Veradermics Reports Strong Performance Amid Clinical Milestones and Funding Success
Veradermics (MANE) has emerged as one of the top-performing NYSE stocks in 2026, driven by positive clinical data for its pipeline asset VDPHL01. Despite a Q1 net loss widening to $27.2 million from $12.4 million year-over-year due to increased R&D and G&A expenses, the company secured significant funding through a follow-on offering, extending its cash runway into 2030.
Topics: clinical trial results funding pipeline progress stock performance